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Background: Currently, there is no universally accepted prognostic classification for
patients (pts)withmetastatic hormone sensitive prostate cancer (mHSPC) treatedwith
androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with
low volume (LV), per CHAARTED trial definition, mHSPC, and those who relapse after
prior local therapy (PLT) have longer overall survival (OS) compared to high volume
(HV) and de-novo (DN), respectively. Using a hospital-based registry, we aimed to
assess whether a classification based on time of metastatic disease (PLT vs DN) and
disease volume (LV vs HV) are prognostic for mHSPC pts treated with ADT.
Methods: A retrospective cohort of consecutive patients with mHSPC treated with
ADT between 1990 and 2013 was selected from the prospectively collected Dana-
FarberCancer Institute database and categorized asDNorPLT andHVor LV, at timeof
ADT start. Primary and secondary endpoints were OS and time to castration-resistant
prostate cancer (CRPC), respectively, which were measured from date of ADT start
using Kaplan-Meier method. Multivariable Cox proportional hazards models using
known prognostic factors was used.
Results: The analytical cohort consisted of 436 patients. The median OS and time to
CRPC for PLT/LV were 92.4 (95%CI: 80.4-127.2) and 25.6 (95%CI: 21-35.7) months
and 43.2 (95%CI: 37.2-56.4) and 12.2 (95%CI: 9.8-14.8) months for DN/HV,
respectively, whereas intermediate values were observed for PLT/HV and DN/LV.
A robust gradient for both outcomes was observed (Trend test P < 0.0001) in the four
groups. In a multivariable analysis, DN presentation, HV, and cancer-related pain were
independent prognostic factors.
Conclusions: In our hospital-based registry, time of metastatic presentation and
disease volume were prognostic for mHSPC pts treated with ADT. This simple
prognostic classification system can aid patient counseling and future trial design.
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1 | INTRODUCTION
Androgen deprivation therapy (ADT) has been the standard of care for
mHSPC for almost 80 years and generally results in a prompt decrease
of tumor burden, palliation of pain, and fall of serum levels of prostate
specific antigen (PSA).1 However, the efficacy of ADT substantially
varies, with some patients dying within 2 years and others living longer
than 10 years2 and a small minority showing primary resistance to
ADT.1,3,4 The mechanisms underlying this variability have been
extensively investigated in the past and an array of factors including
biological ones, such steroid receptor expression and androgens levels,
as well as clinical factors, such asmetastatic burden and cancer-related
pain, have been correlated with clinical outcome in several studies.5–10
Nonetheless, to date no prognostic classification is universally
accepted for use in clinical practice or clinical trial conduct.
Between 2014 and 2017 docetaxel and abiraterone acetate were
shown to increase the longevity of men commencing ADT for
mHSPC.11–14 In particular, the CHAARTED trial showed a clear
benefit for patients with a high burden of disease. The E3805
investigators defined high volume (HV) disease as the presence of
visceral metastases and/or four or more osseous metastases of which
at least one extra-axial with the remainder being low volume (LV).13
Subgroup analyses of patients treated with ADT alone demonstrated
that the prospectively defined LV patients and those relapsing with
metastases after prior local therapy with curative intent (PLT) had a
longer overall survival (OS) compared to patients with HV disease and
men with newly diagnosed with mHSPC (de-novo, DN).15–17
Identification and use of simple and reliable clinical factors
prognostic of survival with ADT would facilitate treatment decision
making, clinical trial design, biological interrogations, and personalized
therapy. This study aimed to assess whether a classification system
based on time of metastatic disease occurrence (PLT or DN) and
volume of disease (LV or HV) is prognostic for patients with mHSPC
treated with ADT in a prospectively collected hospital-based registry.
2 | MATERIALS AND METHODS
From the Dana-Farber Cancer Institute prospectively collected and
institutional review board (IRB) approved database we retrospectively
identified consecutive patients with histologically confirmed and
radiologically evaluable mHSPC who were commencing ADT (orchi-
ectomy or luteinizing hormone-release hormone analogues) between
1990 and 2013. Sixty-six patients who at the time of ADT start had
received prior systemic therapy or previous ADT or had no disease
volume data or no notation of PLT versus DN were excluded from the
analysis. The resultant cohort was stratified by time of metastatic
disease presentation (PLT or DN) and volume of disease (LV or HV) at
time of ADT start, into four groups: PLT/LV, PLT/HV, DN/LV, DN/HV
(Figure 1). The primary endpoint of the study was overall survival (OS),
defined as time from ADT start to death from any cause or censored at
last follow-up date, and secondary endpoint was time to castration-
resistance prostate cancer (CRPC), defined per Prostate Cancer
Working Group 3 definition.18 For those patients who, despite PSA
not having increased ≥ 1 ng/mL above nadir level and the absence of
radiographic or symptomatic progression, were given a secondary
hormonal manipulation as combined androgen blockade, CRPC was
deemed when PSA ≥ 1 ng/mL on the secondary manipulation. Data on
metastatic burden and sites were gathered from bone or CT or MRI
scans performed within 6 months prior to start of ADT. The volume of
disease was determined per E3805 investigators’ definition of LV
versus HV.13 Serum PSA and alkaline phosphatase (ALP) levels were
collected from routine laboratory tests carried out within 4 months
prior to ADT initiation. Patients’ age, race, biopsy Gleason score (GS),
year of diagnosis, Eastern Cooperative Oncology Group (ECOG)
performance status (PS), and cancer-related pain (pain), and follow up
data were assembled from clinical records. Year of diagnosis was
classified by whether <2004, 2004-2009, or >2009 considering the
time frames where new agents were introduced in the therapeutic
paradigm of prostate cancer. ECOG PS was categorized in = 0 and ≥1
and pain was evaluated whether present or absent at ADT start.
Finally, the extent of disease was classified as node only, bone plus/
minus node, or viscera plus any.
The distribution of the outcomemeasureswas estimated using the
Kaplan-Meier method, including median time to event and its 95%
confidence interval (CI). Cox proportional hazards model assessed
disease outcomes according to the composite prognostic risk groups
defined by time of metastatic disease presentation and disease volume
groups and provided estimates of hazard ratio (HR) (95%CI) for the
comparison by groups. In addition, cox proportional hazardsmodelwas
used to evaluate the associations between disease outcomes and
potential baseline covariates such as biopsy GS, median PSA, ECOG
PS, extent of disease, pain, age, and year of diagnosis.9,10 A
multivariable Cox proportional hazards model assessed the relation-
ship between outcomes and risk groups after adjusting for the
putatively prognostic covariates which were significant in the
univariate analysis—median PSA, year of diagnosis, extent of disease,
and pain.9,10 This was conducted in a subset of 335 patients with data
of all covariates available.
FIGURE 1 Study flowchart. ADT, androgen deprivation therapy;
DN, de-novo; HV, high volume; LV, low volume; mHSPC, metastatic
hormone sensitive prostate cancer; PLT, prior local therapy
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3 | RESULTS
Overall, of 502 patients with mHSPC, 436 were evaluable for this
analysis (Figure 1), 192 with PLT and 244 were DN at time of ADT
initiation. Patients’ baseline demographic and clinical characteristics
are summarized in Table 1. Most patients were white, <65 years, did
not have cancer-related pain, and had ECOG PS = 0, at ADT
commencement. Biopsy GS was ≥8 in 72% of DN patients while in
PLT cohort it was 34% of men. Patients who were considered having
developed CRPC when PSA ≥ 1 ng/mL on a secondary hormonal
manipulation were 82 (19%) and they were quite evenly distributed
across the study cohorts (Supplementary Table S1). The distributions
of the four risk groups were as follows: 29% PLT/LV, 15% PLT/HV,
22% DN/LV, 34% DN/HV (Table 2). A statistically significant (Trend
test P < 0.0001) gradient was noted in both median OS and time to
CRPCwithin the four groups in favor of PLT/LV. Namely, patients with
PLT/LV showed longer median OS and time to CRPC at 92.4 (95%CI:
80.4-127.2) and 25.6 (95%CI: 21-35.7) months, respectively.
TABLE 1 Patient characteristics at time of presentation with metastatic disease
Characteristics Total N = 436 Prior local therapy, N = 192 De-novo, N = 244
Age, years
Median 62 61 63
Range 56–68 57-66 55-70
Race, N (%)
White 373 (86) 174 (91) 199 (82)
Unknown 63 (14) 18 (9) 45 (18)
Biopsy gleason score, N (%)
≤6 74 (17) 53 (28) 21 (9)
7 103 (24) 65 (34) 38 (15)
8-10 216 (49) 62 (32) 154 (63)
Unknown 43 (10) 12 (6) 31 (13)
Year of diagnosis, N (%)
<2004 200 (46) 114 (60) 86 (35)
2004-2009 193 (44) 64 (33) 129 (53)
>2009 27 (6) 4 (2) 23 (9)
Unknown 16 (4) 10 (5) 6 (3)
Extent of disease, N (%)
Node only 78 (18) 44 (23) 34 (14)
Bone plus/minus node 333 (76) 133 (69) 200 (82)
Viscera plus any 25 (6) 15 (8) 10 (4)
Cancer related pain, N (%)
No pain 259 (59) 134 (70) 125 (51)
Pain 98 (23) 32 (16) 66 (27)
Unknown 79 (18) 26 (14) 53 (22)
ECOG performance status, N (%)
0 308 (71) 150 (78) 158 (65)
≥1 45 (10) 15 (8) 30 (12)
Unknown 83 (19) 27 (14) 56 (23)
Median PSA, ng/mL (IQR) 31 (12-140) 14 (6-39) 75 (21-325)
Unknown, N (%) 11 (3) 5 (3) 6 (2)
Alkaline phosphatase, N (%)
Normal 130 (30) 86 (45) 44 (18)
Abnormal 45 (10) 18 (9) 27 (11)
Unknown 261 (60) 88 (46) 173 (71)
Median follow-up, years (95%CI) 9.6 (8.9-10.5) 8.9 (7.9-10.2) 10.5 (9.6-15)
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Intermediate results were observed in PLT/HV and DN/LV which
yielded a similar OS, 55.2 (95%CI: 44.4-80.4) and 51.6 (95%CI: 48-78)
months, and time to CRPC, 15 (95%CI: 12.2-23.9) and 17.9 (95%CI:
12.8-21.1) months. DN/HV cohort showed the shortest OS and time
to CRPC, which were 43.2 (95%CI: 37.2-56.4) and 12.2 (95%CI: 9.8-
14.8) months, respectively. Compared to patients with PLT/LV
(reference group), those in the other three cohorts had a statistically
significant higher risk of developing CRPC or dying. Particularly, DN/
HV patients showed a robust greater than two-fold higher risk of
developing CRPC (HR = 2.09; 95%CI: 1.63-2.66) or death (HR = 2.48;
95%CI: 1.83-3.36) (Table 2). Median OS and time to CRPC Kaplan-
Meier curves further highlight the existence of three distinct
categories: a good prognosis group represented by PLT/LV, an
intermediate prognosis group with either PLT/HV or DN/LV, and a
poor prognosis group corresponding to DN/HV (Figure 2).
Inunivariateanalysis,while covariatesmedianPSAandpain showed
a robust association with both OS and time to CRPC, year of diagnosis
<2004 versus >2009was shown to be associated with a shorter time to
CRPC but not to death (Table 3). Furthermore, patients with node only
metastases had a significantly longerOS and time to CRPC compared to
bone plus/minus node metastases. Therefore, we further assessed the
prognostic properties of the composite risk groups with a multivariable
Cox model, adjusted for median PSA, pain, year of diagnosis and extent
of disease (Table 4). Consistently with the results of the univariate
model, PLT/LV was shown to be the group with the significantly lowest
risk of CRPCor death comparedwith the other covariates. This suggests
that time of metastatic disease presentation and volume of disease are
independent prognostic factors. In addition, while presence of cancer-
relatedpainwas confirmed tobeasignificantpredictive factor of shorter
survival (HR = 1.4, 95%CI: 1.04-1.89; P = 0.029) and time to CRPC
(HR = 1.3, 95%CI: 1-1.7; P = 0.054), median PSA and year of diagnosis
<2004 versus >2009 were associated with a shorter time to CRPC but
not OS (Table 4).
4 | DISCUSSION
High metastatic burden and DN presentation are known to be
associated with poor prognosis for mHSPC patients treated with
ADT.15–17 The present study showed that time of metastatic disease
TABLE 2 Overall survival and time to CRPC




(95%CI) HR (95%CI) P-trend Log-rank P-value
PLT/LV 125 (50) 125 (29) 74 (4.2) 92.4 (80.4-127.2) 1 <0.0001 < 0.0001
PLT/HV 67 (75) 67 (15) 42 (6.2) 55.2 (44.4-80.4) 1.9 (1.31-2.75)
DN/LV 96 (70) 96 (22) 43 (5.2) 51.6 (48-78) 1.64 (1.16-2.31)
DN/HV 148 (84) 148 (34) 37 (4) 43.2 (37.2-56.4) 2.48 (1.83-3.36)




HR (95%CI) P-trend Log-rank P-value
PLT/LV 125 (100) 125 (29) 83 (3.3) 25.6 (21-35.7) 1 <0.0001 <0.0001
PLT/HV 67 (100) 67 (15) 70 (5.6) 15 (12.2-23.9) 1.62 (1.2-2.19)
DN/LV 96 (100) 96 (22) 76 (4.4) 17.9 (12.8- 21.1) 1.61 (1.23- 2.11)
DN/HV 148 (100) 148 (34) 57 (4.1) 12.2 (9.8-14.8) 2.09 (1.63-2.66)
P-trend: 1 degree of freedom (df) Wald test P-value to indicate the (trend) association. Log-rank test (score test) P-value: to assess the heterogeneity of the
risk groups. DN, de-novo; HV, high volume; LV, low volume; PLT, prior local therapy; SE, standard error.
FIGURE 2 Overall survival and time to CRPC. ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; DN, de-novo;
HV, high volume; LV, low volume; OS, overall survival; PLT, prior local therapy. [Color figure can be viewed at wileyonlinelibrary.com]
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occurrence (PLT versus DN) and volume of disease (LV versus HV) of
mHSPC patients in a hospital-based registry are significantly
independent prognostic factors and that a classification based on
these two factors is prognostic for survival and time to CRPC as it
identifies three distinct categories of patients with good, intermediate,
and poor outcomes (Figure 2). Particularly, patients with PLT/LV
seemed to benefit the most from ADT with a prolonged median OS of
92.4 months and time to CRPC of 25.6 months, respectively, whereas,
patients with DN/HV characteristics had less than half the survival and
time to CRPC, 43.2 and 12.2 months, respectively, and their risk of
shorter survival and time to CRPC was more than double (Table 2).
These results are consistent with those of the post-hoc analysis of
the CHAARTED trial and of the CHAARTED-GETUG-AFU15 combined
study.16,17 Similarly to our report, in both these analyses, patients were
classifiedby timeofmetastatic diseaseoccurrence andextent of disease
burden and the OS of each of the four groups was evaluated.
Consistently with our study, the PLT/LV cohort experienced the best
prognosis with ADT, while DN/HV had the worst outcomes and a
halving of survival compared to PLT/LV in the GETUG-AFU15 dataset
(34.0 [28.5-43.6] vs NR [69.8-NR] months).17 Collectively, these results
suggest that DN/HV disease is a biologically distinct entity which is less
androgendependent andhasamoreaggressivephenotype. Inour study,
some biological evidence is provided by the observation that DN
patients have a two-fold higher rate of biopsyGS ≥ 8 (72%) compared to
PLT (34%). Besides, absence of pain and ECOG PS = 0 were more
common among patients with PLT than DN, 70% and 78% versus 51%
and 65%, respectively, andmedian PSA at ADT start was notably higher
in DN compared to PLT (Table 1). Furthermore, in both above-
mentioned post-hoc trial-based analyses, DN/HV was shown to be the
only group to benefit from the chemohormonal regimen. While the
survival improvement was only numerical in the GETUG-AFU15
analysis, it was statistically significant in the CHAARTED study
(HR = 0.63; P = 0.0004).16,17 These data further corroborate the
hypothesis that DN/HV may be a less testosterone dependent disease
for which the addition of chemotherapy to ADT can bemore beneficial.
Conversely, there appears to be no benefit of chemotherapy in PLT/LV
patients who have a prolonged response to ADT.16,17 The intermediate
prognostic group, PLT/HV or DN/LV, represents a greyer area as some
of these patients may profit from the addition of docetaxel to hormone
therapy, which highlights the need of accurate biomarkers for
identification, whereas other subjects would probably benefit more
from a different treatment. In this respect, while recent data from the
TABLE 3 Associations of potential baseline covariates with CRPC and OS
Covariates CRPC, HR (95%CI) P-value OS, HR (95%CI) P-value
Gleason score = 7 vs ≤6 (ref) 0.9 (0.67-1.22) 0.508 0.85 (0.58-1.24) 0.398
Gleason score ≥8 vs ≤6 (ref) 1.25 (0.96-1.63) 0.093 1.26 (0.91-1.74) 0.166
Median PSA (one log10 unit change) 1.33 (1.19-1.48) <0.001 1.23 (1.09-1.4) 0.001
Median age >62 vs ≤62 years (ref) 1.04 (0.85-1.26) 0.721 1.19 (0.94-1.49) 0.142
ECOG PS ≥1 vs = 0 (ref) 1.22 (0.89-1.67) 0.217 1.23 (0.86-1.77) 0.257
Pain vs No pain (ref) 1.47 (1.17-1.86) 0.001 1.56 (1.19-2.04) 0.001
Year of diagnosis <2004 vs >2009 (ref) 0.49 (0.32-0.73) <0.001 0.74 (0.4-1.37) 0.337
Year of diagnosis 2004-2009 vs >2009 (ref) 0.92 (0.62-1.38) 0.694 1.32 (0.71-2.44) 0.377
Extent of disease Bone plus/minus node vs Node only (ref) 1.28 (1-1.65) 0.048 1.58 (1.14-2.19) 0.006
Extent of disease Viscera plus any vs Node only (ref) 0.92 (0.59-1.45) 0.722 1.12 (0.63-2) 0.698
Trend-test, test of trend effect (Bone only vs Node only vs Bone plus node vs Viscera plus any). CRPC, castration-resistant prostate cancer; OS, overall
survival; ref, reference.
TABLE 4 Multivariate analysis adjusted for potentially significant covariates in a subset of N = 335 with all available covariates data
Groups Time to CRPC, HR (95%CI) P-value OS, HR (95%CI) P-value
PLT/HV vs PLT/LV (ref) 1.71 (1.19-2.45) 0.004 1.95 (1.24-3.06) 0.004
DN/LV vs PLT/LV (ref) 1.12 (0.78-1.62) 0.541 1.4 (0.88-2.22) 0.151
DN/HV vs PLT/LV (ref) 1.47 (1.04-2.07) 0.028 1.79 (1.16-2.76) 0.009
Median PSA (one log10 unit change) 1.24 (1.07-1.44) 0.004 1.05 (0.88-1.26) 0.585
Pain vs no pain (ref) 1.3 (1-1.7) 0.054 1.4 (1.04-1.89) 0.029
Year of diagnosis <2004 vs >2009 (ref) 0.82 (0.53-1.28) 0.386 1.03 (0.54-1.96) 0.932
Year of diagnosis 2004–2009 vs >2009 (ref) 0.4 (0.25-0.64) <0.001 0.59 (0.3-1.15) 0.123
Extent of disease bone plus/minus node vs Node only (ref) 0.93 (0.68-1.28) 0.672 1.19 (0.79-1.8) 0.398
Extent of disease Viscera plus any vs Node only (ref) 0.73 (0.42-1.26) 0.254 0.81 (0.39-1.68) 0.568
DN, de novo; HV, high volume; LV, low volume; PLT, prior local therapy; ref, reference.
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early analysis of the large phase III randomized LATITUDE trial support
the validity of the addition of abiraterone acetate plus prednisone to
ADT as a new option for mHSPC patients with DN disease and poor
prognostic features (HR = 0.62, 95%CI: 0.51-0.76; P < 0.001), the latest
results of the multiarm STAMPEDE trial show that this combination is
more effective than ADT alone for mHSPC patients (HR = 0.61; 95%CI:
0.49-0.75).11–12Notably, 94%of the STAMPEDEmetastatic population
had DN disease but, since disease burden in this subgroup was not
defined, the classification in LV versus HV cannot be done. In addition,
more research focusing on pts with PLT and/or LV disease would be
needed to confidently state that the upfront combination of ADT and
abiraterone is better than sequential treatment in these unique patient
cohorts.
The three prognostic groups identified in the present study may
predict distinct outcomes with different therapies and this classifica-
tion could ultimately be an efficient tool to personalize treatment and
avoid unnecessary toxicity. A definitive confirmation could come from
future prospective studies which should stratify patients using this
prognostic system based on history of prior local therapy and volume
of metastases.
In the past, several studies proposed different prognostic
classifications for mHSPC treated with ADT. Most of them took into
consideration the disease burden, often defined according to the
number of metastases on the bone scan9,19 or whether axial or extra-
axial.8,9 While identifying the correct number of metastases can be
challenging, especially when confluent, a selection based solely on
location may be misleading, especially in case of a solitary appendicular
lesion. The Glass prognostic system was based on the latter and other
factors, such as ECOG PS, PSA levels, and biopsy GS, validated from a
large randomized clinical trial dataset.9 As in our study, this classification
would allow identifying three prognostic groups predictive of survival.
However, a statistical limitation of the Glass classification studywas the
low R2 values for the test and validation model (13% and 12%,
respectively). Besides, while this classification based on four factors
identifies prognostic groups with significantly different outcomes,
segregation is not intuitive and lacks the reproducibility necessary for
routine clinical usewhichwas observedwith our easily applicablemodel
of stratificationbasedon twoclinicallymeaningful factors. Furthermore,
in our univariate analysis, ECOGPS and biopsyGS did not result in being
independent prognostic factors (Table 3). It could be postulated that
both these covariates were trumped by the more potent prognostic
factors of timeofmetastatic disease presentation and volumeof disease
as these are clinical variables that presumably represent disease biology
more accurately. Namely, DN/HV disease is usually rapidly progressive
and thus probably represents a more aggressive multiclonal entity
compared to PLT/LV.
Conversely, in multivariate analysis, the absence of cancer-related
pain at time of start of ADT was confirmed an independent predictive
factor of longer survival and time to CRPC for mHSPC patients
(Table 3). However, this association was not as statistically robust as
for PLT/LV and data regarding pain were extracted from clinical chart
notations rather than from standardized pain assessments, which may
limit the validity of this finding. Nevertheless, it should be noted that
the absence of cancer-related pain has been found to be significantly
related to survival in several studies in the past.20,21
The retrospective nature of the present study, the small size of the
cohorts, and thewide accrual timewindowduringwhich several new life-
extending agents emerged, admittedly represent limitations which
prevent us from drawing general conclusions. Additionally, further work
for a complete evaluation of this simple prognostic classification requires
assessment in different ethnic and socio-economic populations as well as
part of a prospective validation study. However, our prognostic
classification based on the volume of metastases and time of metastatic
presentation provides an easy and intuitive model of stratification which
would aid in the design of large-scale clinical trials allowingmore accurate
identification of the study population and more balanced randomization.
Inaddition, avalidatedclassificationsystemwould improveunderstanding
of findings fromphase II studiesofnovel treatmentsandguidesubsequent
larger trials. Finally, as also shown in the CHAARTED and CHAARTED-
GETUG-AFU15 combined analyses, it would also help in treatment-
decision making process. Nevertheless, there remains an unmet need for
molecular prognostic and predictive biomarkers of treatment in this
setting to further advance personalized treatment.
5 | CONCLUSIONS
The prognostic system based on time of metastatic presentation and
E3805 defined volume of disease can be easily applied as a prognostic
tool for counseling patients with mHSPC treated with ADT and can be
a simple and reproducible stratification system for future clinical trials.
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